| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (NCT03399773) | Fred Hutchinson Cancer Center | 2022-05-10 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767) | University of Washington | 2022-02-04 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606) | City of Hope Medical Center | 2020-10-20 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting (NCT04128501) | M.D. Anderson Cancer Center | 2020-05-05 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (NCT03779854) | Fred Hutchinson Cancer Center | 2019-08-29 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation (NCT03683433) | M.D. Anderson Cancer Center | 2018-09-18 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant (NCT03267186) | Andrew Rezvani | 2017-09-12 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02728050) | University of Washington | 2016-12-01 |
| Personalized NK Cell Therapy in CBT (NCT02727803) | M.D. Anderson Cancer Center | 2016-05-19 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies (NCT02529813) | M.D. Anderson Cancer Center | 2015-12-16 |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT02159495) | City of Hope Medical Center | 2015-12-15 |
| Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT02399917) | M.D. Anderson Cancer Center | 2015-04-20 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (NCT02397720) | M.D. Anderson Cancer Center | 2015-04-07 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD (NCT02220985) | Fred Hutchinson Cancer Center | 2015-03-23 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (NCT02135874) | M.D. Anderson Cancer Center | 2014-10-27 |
| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention (NCT01951885) | Case Comprehensive Cancer Center | 2014-07-07 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia (NCT02115295) | M.D. Anderson Cancer Center | 2014-05-19 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children (NCT01858740) | Fred Hutchinson Cancer Center | 2014-04-10 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (NCT02044796) | Fred Hutchinson Cancer Center | 2014-01-23 |
| Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01804101) | Fred Hutchinson Cancer Center | 2013-05-07 |
| NK Cells in Cord Blood Transplantation (NCT01619761) | M.D. Anderson Cancer Center | 2013-05-03 |
| Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (NCT01690520) | Nohla Therapeutics, Inc. | 2012-12-11 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01028716) | Fred Hutchinson Cancer Center | 2010-05-19 |
| Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant (NCT00796068) | Fred Hutchinson Cancer Center | 2009-02-24 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |